Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2026, Genomma Lab InternacionalB de CV has a Sloan Ratio of 1.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Genomma Lab InternacionalB de CV (MEX:LABB) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Genomma Lab InternacionalB de CV has a Sloan Ratio of 1.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Genomma Lab InternacionalB de CV Sloan Ratio % Related Terms
Genomma Lab InternacionalB de CV Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Sloan Ratio % Chart
MEX:LABB vs ZTS, UTHR, VTRS: Sloan Ratio % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Sloan Ratio % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Sloan Ratio % falls into.
Genomma Lab InternacionalB de CV Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Genomma Lab InternacionalB de CV's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was 354.966 (Jun. 2025 ) + 434.066 (Sep. 2025 ) + 319.636 (Dec. 2025 ) + 494.647 (Mar. 2026 ) = MXN1,603 Mil.
Genomma Lab InternacionalB de CV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 509.532 (Jun. 2025 ) + 440.33 (Sep. 2025 ) + 1255.694 (Dec. 2025 ) + -229.167 (Mar. 2026 ) = MXN1,976 Mil.
Genomma Lab InternacionalB de CV's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -101.409 (Jun. 2025 ) + -114.799 (Sep. 2025 ) + -322.914 (Dec. 2025 ) + -80.792 (Mar. 2026 ) = MXN-620 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Sloan Ratio % of 1.00% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Genomma Lab InternacionalB de CV and its competitors.
Is Genomma Lab InternacionalB de CV's Sloan Ratio % too high?
Genomma Lab InternacionalB de CV's current Sloan Ratio % is 1.00%. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Sloan Ratio % compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's Sloan Ratio % of 1.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Drug Manufacturers company?
A good Sloan Ratio % depends on the Drug Manufacturers industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current Sloan Ratio % is 1.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.66, compared to a current price of MXN15.56 — trading 11.9% below its estimated fair value. The current Sloan Ratio % is 1.00%. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Sloan Ratio % is 1.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.56 is trading 11.9% below its estimated GF Value™ of MXN17.66.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Sloan Ratio %: 1.00%
GF Value™: MXN17.66 vs. price of MXN15.56 (11.9% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
